Trial reportThe Lancet. Microbe2026
Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial.
Trial report in The Lancet. Microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05534984 (A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundMonkeypox virus (MPXV) has emerged as a global public health threat. Three phase 3 trials of tecovirimat showed no substantial clinical benefit. We report virus isolation and sequencing results from the Advancing Clinical Therapeutics Globally (ACTG) A5418-The Study of Tecovirimat for Human Mpox (A5418-STOMP).
methodsACTG A5418-STOMP was a phase 3 randomised, placebo-controlled, double-blind trial (NCT05534984) with an additional open-label arm enrolling paediatric, pregnant, severely immunosuppressed, or severe-disease participants. Day 1 (baseline), day 8, and day 15 index lesion skin swabs were used for virus isolation. Deep sequencing of the F13L gene was performed on index and new skin lesions, and on rectal, oral, vaginal, blood, and urine specimens through day 57. A predefined list of resistance-associated mutations (RAMs) was used to classify participants as having no RAMs, transmitted RAMs, or treatment-emergent RAMs. Proportions were compared using Fisher's exact tests; duration-normalised log
findingsAmong participants who were culture-positive on day 1 with available day 8 swabs, five (9%) of 53 in the randomised tecovirimat arm, three (12%) of 25 in the placebo arm, and eight (12%) of 67 in the open-label arm were culture-positive on day 8 (p=0·71). Among participants with day 1 and longitudinal sequencing data available, treatment-emergent resistance was observed in one (2%) of 54 of the randomised tecovirimat arm, zero of 29 of the placebo arm, and six (6·5%) of 92 of the open-label arm. Participants with treatment-emergent resistance had significantly higher longitudinal viral loads (p=0·0014) and lower clinical resolution rates by day 57 (28·6% vs 94·7%; p=3·8 × 10
interpretationAlthough treatment-emergent resistance to tecovirimat was rare overall, it was observed more often in participants living with advanced HIV and profoundly impaired cellular immunity, leading to persistently higher viral loads and delayed clinical recovery. Tecovirimat therapy of mpox infection did not reduce the frequency of MPXV isolation from skin swabs. Novel therapeutic options are needed to address mpox infection.
fundingAdvancing Clinical Therapeutics Globally and the National Institute of Allergy and Infectious Diseases, US National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.